1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

@inproceedings{Heeswijk20111244TP,
  title={1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR},
  author={Remko van Heeswijk and Ann Vandevoorde and Peter Verboven and Griet Boogaerts and Els De Paepe and Rodica Van Solingen-Ristea and Varun Garg and Maria Gloria Beumont},
  year={2011}
}
Protease Inhibitor Telaprevir Rolf van Heeswijk,1 Ann Vandevoorde,1 Peter Verboven,2 Griet Boogaerts,1 Els De Paepe,1 Rodica van Solingen-Ristea,1 Varun Garg,3 Maria Beumont1 1Tibotec BVBA, Beerse, Belgium; 2Janssen Research and Development, Beerse, Belgium; 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA Poster 1244 Abstract 654 Corresponding author: Rolf van Heeswijk Tibotec BVBA Turnhoutseweg 3 
BETA

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.

  • Journal of hepatology
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

  • The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…